Production (Stage)
MediPharm Labs Corp.
LABS.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 78.13% | 39.37% | -7.74% | 29.52% | -30.75% |
| Total Depreciation and Amortization | -26.12% | 5.53% | -28.90% | -8.84% | 11.20% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 146.82% | -198.38% | -12.50% | 5.47% | 80.83% |
| Change in Net Operating Assets | -503.58% | -8.89% | 253.19% | -207.30% | -82.90% |
| Cash from Operations | -175.35% | -57.03% | 58.64% | -3.69% | -204.48% |
| Capital Expenditure | 6.69% | -29.75% | 40.83% | -162.18% | 82.17% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -96.22% | 209.63% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 6.69% | -29.75% | 5.47% | -106.57% | -87.70% |
| Total Debt Issued | -- | -100.00% | -93.32% | -- | -- |
| Total Debt Repaid | 21.36% | 85.30% | -1,398.04% | 43.12% | 31.20% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -29.11% | 295.00% | -77.53% | -56.16% | 35.33% |
| Cash from Financing | 16.47% | 89.30% | -425.43% | 1,121.63% | 72.33% |
| Foreign Exchange rate Adjustments | 133.04% | -354.55% | -13.73% | 71.91% | 102.37% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -125.90% | 52.88% | -211.06% | 12.68% | -121.16% |